NVIC Articles

Disease-Vaccine-Landing-Page

Disease-Vaccine-Landing-Page

Latest articles

Browse Articles

Placeholder image
Page

On Mar. 10, 2020, the Secretary of Health and Human Services (HHS) invoked the 2005 Public Readiness and Emergency Preparedness (PREP) Act, after declaring that the COVID-19 pandemic was a...

Placeholder image
Page

As of the December 27, 2024 data release, vaccine adverse events submitted to VAERS associated with the Novavax COVID-19 vaccine totaled 706 with 95 noted as serious. Included in these...

Placeholder image
Page

According to the Fact Sheet for Health Care Providers administering Novavax COVID-19 vaccine, the most common side effects reported following vaccination were injection site pain and tenderness, malaise/fatigue, muscle pain,...

Placeholder image
Page

Novavax COVID-19 Vaccine Clinical Trial DataMaryland-based Novavax Inc, a biotechnology company which, prior to its COVID-19 vaccine, had never successfully delivered a product to market,  developed an experimental vaccine using...

Placeholder image
Page

As of the December 27, 2024 data release, vaccine adverse events submitted to VAERS associated with the Johnson & Johnson/Janssen COVID-19 vaccine totaled 99,696, with 17,806 noted as serious. Included...

Placeholder image
Page

In January 2022, the Pharmacovigilance and Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) reported that a reasonable association existed between the Janssen/Johnson & Johnson and AstraZeneca, an...

Placeholder image
Page

On January 11, 2022, the FDA updated the Johnson & Johnson/Janssen COVID-19 Vaccine Fact Sheet for Health Care Providers Administrating with information regarding the serious risk of Immune Thrombocytopenia (ITP)...

Placeholder image
Page

On July 13, 2021, the FDA announced revisions to the Fact Sheet for Healthcare Providers administering the Janssen/Johnson & Johnson COVID-19 vaccine and the Fact Sheet for Recipients and Caregivers...

Placeholder image
Page

On April 13, 2021, the FDA and CDC paused use of the vaccine after serious blood clots were reported in women between the ages of 18 and 49.  By April...

Placeholder image
Page

On June 1, 2023, the FDA revoked the EUA for Johnson & Johnson/Janssen COVID-19 vaccine. According to the FDA, Janssen BioTech had requested the voluntary withdrawal of its COVID-19 vaccine...

Topics
Select disease / vaccine